Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction; relationship to serum growth hormone levels (Study 3)

John L Yovich; Syeda Zaidi; Minh DK Nguyen; Peter M Hinchliffe

doi:10.30574/gscbps.2020.13.3.0333

Authors

John L Yovich Department of Pharmacy and Biomedical Sciences Curtin University Perth, Western Australia Australia 6845 Current address.
Syeda Zaidi Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Malaya Lembah Pantai, Kuala Lumpur Malaysia 59100.
Minh DK Nguyen PIVET Medical Centre Perth, Western Australia Australia 6007.
Peter M Hinchliffe PIVET Medical Centre Perth, Western Australia Australia 6007.

DOI:

https://doi.org/10.30574/gscbps.2020.13.3.0333

Keywords:

Human growth hormone (hGH), Insulin-like growth factor-1 (IGF-1), Insulin-like growth factor binding protein-3 (IGFBP-3), IGF profile (IGF-1, IGFBP-3 and IGF Ratio), IGFBP-3/ IGF-1 ratio (IGF Ratio), Assisted reproductive technology (ART), In vitro fertilization (IVF).

Abstract

Extending from our first two studies examining the IGF profile (IGF-1, IGFBP-3 and the ratio of IGFBP-3/ IGF-1) in women presenting for assisted reproductive technologies (ART), this study examines its relevance to the testing of human growth hormone (hGH) levels on the same blood sample. These were taken in the morning during the early follicular phase of the woman’s menstrual cycle and included 408 women who were ART-naïve, undertaking the tests as part of an assessment cycle prior to any ART treatment. The growth hormone levels were also tested on a further 945 women classified as ART-interval cases. It was shown that the vast majority of hGH levels (73%) were very low at <1.0 ng/mL and 22% are extremely low <0.1 ng/mL, close to the detection level of the chemiluminescent immunoassay (0.03 ng/mL). Only 12% of hGH levels were recorded in the range ≥3.0 ng/mL, levels which exclude adult growth hormone deficiency (AGHD). Although IGF-1 levels are regarded as a screening test for AGHD, our studies showed no correlation between hGH levels and the entire range of IGF-1 levels, neither across IGFBP-3 levels, nor across IGF Ratios, albeit there was an apparent inverse trend for the latter. Across the entire age range, the hGH levels were not statistically different among neither the ART-naïve nor the ART-interval women. Furthermore, hGH levels were not different among the clinical parameters of stature or BMI; nor for ovarian reserve parameters AMH or AFC. It is concluded that serum hGH screening probably has very limited value as a screening test for potential AGHD.

Metrics

Metrics Loading ...

References

Yovich JL, Craft IL. Founding pioneers of IVF: Independent innovative researchers generating livebirths within 4 years of the first birth. Reprod Biol. 2018; 18: 317-323.

Yovich JL. Founding pioneers of IVF Update: Independent innovative researchers generating livebirths within 4 years of the first birth. Reprod Biol. 2020; 20: 111-113.

Annual Capri Workshop Group. IVF, from the past to the future: the inheritance of the Capri Workshop Group. Hum Reprod Open. 2020; 1-9.

Zhang Y, Zhang C, Shu J, Guo J, Chang H-M, Leung PCK, Sheng J-Z, Huang H. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum Reprod Update. 2020; 1-17.

Farquhar C. Add-ons for assisted reproductive technology: can we be honest here? Fertil Steril. 2019; 112(6): 971-972.

Yovich JL, Ye Y, Regan SLP, Keane KN. The evolving concept of poor-prognosis for women undertaking IVF and the notion of growth hormone as an adjuvant; a single-center viewpoint. Front Endocrinol. 2019; 10, 808-14.

Bortoletto P, Spandorfer S. Growth hormone: in search of the holy grail for poor responders (or a felony). Fertil Steril. 2020; 114(1): 63-64.

Yovich JL, Regan SL, Zaidi SN, Keane KN. The concept of growth hormone deficiency affecting clinical prognosis in IVF. Front Endocrinol. 2019; 10: 650.

Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes. 2012; 19: 47-52.

Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011; 96(6): 1587–1609.

Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction; relationship to clinical parameters (Study 1). J Pers Med. 2020; 10: 122.

Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction; relationship to ovarian reserve parameters (Study 2). GSC Biololgical and Pharmaceutical Sciences, 2020, 13(02), 035-053..

Yovich JL. How to Prepare the Egg and Embryo to Maximise IVF Success. In: Monitoring the stimulated IVF cycle. Section II: Stimulation for IVF (Eds: Gabor T Kovacs, Anthony J Rutherford, David K Gardner). Cambridge University Press, Cambridge, UK. 2019; 94-120.

Keane K, Cruzat VF, Wagle S, Chaudhary N, Newsholme P, Yovich J. Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome. Reprod Biol 2017; 17: 51-59.

Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online. 2012; 24(3): 281-292.

Yovich JL, Alsbjerg B, Conceicao JL, Hinchliffe PM, Keane KN. PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome. Drug Des Devel Ther. 2016; 10: 2561–573.

De Palo, EF, De Filippis V, Gatti R, Spinella P. Growth hormone isoforms and segments/fragments: molecular structure and laboratory measurement. Clin Chim Acta. 2005; 364: 67-76.

Ribeiro de Oliveira Longo Schweizer, J, Ribeiro-Oliveira Jr A, Bidlingmaier M. Growth hormone: isoforms, clinical aspects and assays interference. Clin Diabetes Endocrinol. 2018; 4: 18.

Hammer Ø, Harper DAT, Ryan PD. PAST: Paleontological Statistics software package for education and data analysis. Palaentologia Electronica. 2001; 4(1): 9.

Gleicher N, Kushnir VA, Barad DH. Worldwide decline of IVF birth rates and its probable causes. Hum Reprod Open. 2019; 1-7.

Nasioudis D, Minis E, Irani M, Kreines F, Witkin SS, Spandorfer SD. Insulin-like growth factor-1 and soluble FMS-like tyrosine kinase-1 prospectively predict cancelled IVF cycles. J Assist Reprod Genet. 2019; 36(12): 2485-2491.

Man L, Lekovich J, Canon C, Rosenwaks Z, James D. Cycle day-2 insulin-like growth factor-1 serum levels as a prognostic tool to predict controlled ovarian hyperstimulation outcomes in poor responders. Fertil Steril. 2020; 113: 1205-1214.

Steyn FJ, Tolle V, Chen C, Epelbaum J. Neuroendocrine regulation of growth hormone secretion. Compr Physiol. 2016; 6(2): 687-735.

Ipsa E, Cruzat VF, Kagize JN, Yovich JL, Keane KN. Growth Hormone and Insulin-like growth factor in reproductive tissues. Front Endocrinol. 2019; 777: 14.

Regan SLP, Knight PG, Yovich JL, Arfuso F, Dharmarajan A. Growth hormone during in vitro fertilization in older women modulates the density of receptors in granulosa cells, with improved pregnancy outcomes. Fertil Steril. 2018; 110: 1298–309.

Hull KL, Harvey S. Growth hormone and reproduction: a review of endocrine and autocrine, paracrine interactions. Int J Endocrinol, Article ID 234014. 2014; 24.